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of Oxidoreductase Enzymes
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Abstract
In biochemistry, oxidoreductase is a large group of enzymes that are involved in
redox reaction in living organisms and in the laboratory. Oxidoreductase enzymes
catalyze reaction involving oxygen insertion, hydride transfer, proton extraction,
and other essential steps. There are a number of metabolic pathways like glycolysis,
Krebs cycle, electron transport chain and oxidative phosphorylation, drug transfor-
mation and detoxification in liver, photosynthesis in chloroplast of plants, etc. that
require the direct involvements of oxidoreductase enzymes. In addition, degrada-
tion of old and unnecessary endogenous biomolecules is catalyzed by a family of
oxidoreductase enzymes, e.g., xanthine oxidoreductase. Oxidoreductase enzymes
use NAD, FAD, or NADP as a cofactor and their efficiency, specificity, good biode-
gradability, and being studied well make it fit well for industrial applications. In the
near future, oxidoreductase may be utilized as the best biocatalyst in pharmaceuti-
cal, food processing, and other industries. Oxidoreductase play a significant role in
the field of disease diagnosis, prognosis, and treatment. By analyzing the activities
of enzymes and changes of certain substances in the body fluids, the number of
disease conditions can be diagnosed. Disorders resulting from deficiency (quantita-
tive and qualitative) and excess of oxidoreductase, which may contribute to the
metabolic abnormalities and decreased normal performance of life, are becoming
common.
Keywords: biocatalyst, biological application, disease, metabolism, mutation,
oxidoreductase
1. Introduction
Oxidoreductases, which includes oxidase, oxygenase, peroxidase, dehydroge-
nase, and others, are enzymes that catalyze redox reaction in living organisms and
in the laboratory [1]. Interestingly, oxidoreductases catalyze reaction involving
oxygen insertion, hydride transfer, proton extraction, and other essential steps. The
substrate that is oxidized is considered as hydrogen or electron donor, whereas the
substrate that is reduced during reaction as hydrogen/electrons acceptor. Most
commonly, oxidoreductase enzymes use NAD, FAD, or NADP as a cofactor [2].
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Organisms use this group of enzymes for synthesis of biomolecules, degradation
and removal of molecules, metabolism of exogenous molecules like drugs, and so on
[3–5]. Their biochemical property such as efficiency, specificity, good biodegrad-
ability, and being studied well make it fit well for industrial purposes. As a result,
oxidoreductases are being utilized in nutrition, food processing, medicine, and
other chemical synthesis. In the near future, oxidoreductase may be utilized as the
best biocatalyst in pharmaceutical, food processing, and other industries [6, 7].
Enzymes like oxidoreductase play great and significant function in the field of
disease diagnosis, prognosis, and treatment [8]. By analyzing the activities of
enzymes and changes of certain substances in the body fluids, a number of disease
conditions can be diagnosed [9, 10]. The determination of the activity of the oxi-
doreductases is helpful in understanding the metabolic activity of different organs
[8, 11]. For example, the activity of oxidoreductase enzymes in Krebs cycle is
significantly increased during skin infection [12].
There are different disease conditions resulting from deficiency (quantitative
and qualitative) and excess of oxidoreductase, which may contribute to the meta-
bolic abnormalities and decreased normal performance of life [13, 14]. For example,
relative decreases in the activities of NADH dehydrogenase and ubiquinol-
cytochrome c oxidoreductase are highly associated with the developments of
peripheral arterial disease. Another best example is mutation of p450 oxidoreduc-
tase (POR) gene, which leads to insufficiency of P450 enzymes characterized by
defective steroidogenesis. Similarly, deficiency of mitochondrial acetaldehyde
dehydrogenase disturbs normal metabolism of alcohol and leads to accumulation of
acetaldehyde [8, 15, 16]. These conditions in turn affect the normal development
and reproduction.
2. Oxidoreductase in metabolism of foodstuff
Oxidoreductases are a family of enzymes that catalyze redox reactions. Oxido-
reductases catalyze the transfer of electrons from oxidant to reductant [4]. Gener-
ally, oxidoreductases catalyze reactions which are similar to A– + B! A + B– where
A is the oxidant and B is the reductant [17]. Oxidoreductases can be oxidases where
a molecular oxygen acts as an acceptor of hydrogen or electrons and dehydroge-
nases which are enzymes that oxidize a substrate by transferring hydrogen to an
acceptor that is either NAD+/NADP+ or a flavin enzyme. Other classes are oxidore-
ductases enzymes, peroxidases which are localized in peroxisomes and catalyze the
reduction of hydrogen peroxide. Hydroxylases are involved in the addition of
hydroxyl groups to their substrates, and oxygenases are key in the incorporation of
oxygen from molecular oxygen into organic substrates. And reductase enzymes are
involved in the catalysis of reduction reaction [2, 3, 18]. In general, oxidoreductase
enzymes play an important role in both aerobic and anaerobic metabolism. They are
involved in glycolysis, TCA cycle, oxidative phosphorylation, fatty acid, and amino
acid metabolism [5, 19, 20].
3. Oxidoreductase in glycolysis
In glycolysis, the enzyme glyceraldehydes-3-phosphate dehydrogenase catalyzes
the reduction of NAD + to NADH. In order to maintain the redox state of the cell,
this NADH must be re-oxidized to NAD+, which occurs in the oxidative phosphor-
ylation pathway [21].
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G‐3‐Pþ PiþNADþ !
Glyceraldehyde‐3‐phosphate dehydrogenase
1, 3‐BPGþNADHþHþ
(1)
PyruvateþNADHþHþ !
lactate dehydrogenase
lactateþNADþ (2)
4. Oxidoreductase in TCA cycle
A high number of NADH molecules are produced in the TCA cycle. The product
of glycolysis, pyruvate, enters the TCA cycle in the form of acetyl-CoA. Except
leucine and lysine, all twenty of the amino acids can be degraded to TCA cycle
intermediates. And most of the fatty acids are oxidized into acetyl coA through beta
oxidation that enter TCA cycle [19, 22].
The precursor for the TCA cycle comes from lipids and carbohydrates, both of
which produce the molecule acetyl-CoA. This acetyl-CoA enters the eight-step
sequence of reactions that comprise the Krebs cycle, all of which occur inside
mitochondria of eukaryotic cells. TCA or Krebs cycle produces NADH and FADH,
and the reactions are catalyzed by classes of oxidoreductase enzymes [23].
PyruvateþNADþ þ CoA !
pyruvate dehydrogenase
acetyl‐CoAþNADHþHþ þ CO2
(3)
IsocitrateþNADþ !
isocitrate dehydrogenase
alfa‐ketoglutarateþNADHþHþ þ CO2
(4)
α‐ketoglutarateþNADþ þ CoA !
α‐ketoglutarate dehydrogenase
succinyl CoAþNADH
þ CO2
(5)
Succinateþ FADþ !
succinate dehydrogenase
fumarateþ FADH2 (6)
5. Oxidoreductase in electron transport chain and oxidative
phosphorylation
Living cells use electron transport chain to transfer electrons stepwise from
substrates (NADH & FADH2) to a molecular oxygen. The proton gradient which is
generated through electron transport chain runs downhill to drive the synthesis of
ATP. Electron transport chain and oxidative phosphorylation take place in the
matrix of mitochondria, and there are oxidoreductase enzymes impregnated in the
inner mitochondrial membrane, which catalyze these reactions and are engaged in
energy production. NADH:quinone oxidoreductase, also called NADH dehydroge-
nase (complex I), is responsible for the transfer of electrons from NADH to qui-
nones, coupled with proton translocation across the membrane. Succinate:quinone
oxidoreductase, or succinate dehydrogenase (complex II), is an enzyme of the
Krebs cycle, which oxidizes succinate and reduces quinones, in the absence of
proton translocation. Quilon:cytochrome c oxidoreductase (complex III), which
transfers electrons from quinols to cytochrome c and cytochrome c:oxygen oxido-
reductase, an aa3-type enzyme (complex IV), which receives these electrons and
transfers it to oxygen are both oxidoreductase enzymes involved in electron trans-
port chain and oxidative phosphorylation [19, 24, 25] (Figure 1).
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6. Oxidoreductase in drug metabolism
Liver is the principal organ for drug metabolism. The body uses different strat-
egies to metabolize drugs like oxidation, reduction, hydrolysis, hydration, conjuga-
tion, condensation, or isomerization. The main goal of drug metabolism is to make
the drug more hydrophilic and excrete easily. Enzymes involved in drug metabo-
lism are found in many tissues and organs but are more concentrated in the liver.
Rates of drug metabolism may vary among individuals. Some individuals metabo-
lize a drug so rapidly; in others, metabolism may be so slow and have different
effects. Genetic factors, coexisting disorders (particularly chronic liver disorders
and advanced heart failure), and drug interactions are responsible factors for vari-
ation of rate of drug metabolism among individuals [26].
Generally, drug metabolism can be in three phases. In phase I drug metabolism,
oxidoreductase enzymes such as cytochrome P450 oxidases add polar or reactive
groups into drugs (xenobiotics). In phase I reaction, drugs are introduced into new
or modified functional group through oxidation, reduction, and hydrolysis. In Phase
II reactions, modified compounds are in conjugation with an endogenous substance,
e.g., glucuronic acid, sulfate, and glycine. Phase II reactions are synthetic, and
compounds become more polar and thus, more readily excreted by the kidneys (in
urine) and the liver (in bile) than those formed in nonsynthetic reactions. At the
end, in phase III reaction, the conjugated drugs (xenobiotics) may be further
processed, before being recognized by efflux transporters and pumped out of cells.
The metabolism of drug often converts hydrophobic compounds into hydrophilic
products that are more readily excreted [27].
In normal cases, human body wants to remove or detoxify any compounds that
cannot be metabolized otherwise utilized to serve the needs of the body. This
removal process is carried out mainly by the liver. The liver has classes of oxidore-
ductase enzymes that are extremely effective at detoxification and removal of drugs
from the body [5, 18].
6.1 Metabolism of drugs through cytochrome P450 monooxygenase
Oxidation and metabolism of a high number of drugs and endogenous molecules
are catalyzed by a class of oxidoreductase enzymes called cytochrome P450
monooxygenases. Even though they are distributed throughout the body, cytochrome
Figure 1.
Oxidoreductase enzymes involved in electron transport chain and oxidative phosphorylation [18].
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P450 enzymes are primarily concentrated in liver cells. The CYP2D6 isozymes play a
great role in metabolizing certain opioids, neuroleptics, antidepressants, and cardiac
medications. Currently it is going to be understood that difference in the genes for
CYP450 enzymes play to inter-individual differences in the serum concentrations of
drug metabolites, resulting in interpatient variability in drug efficacy and safety [28].
6.2 Metabolism of drugs with flavin-containing monooxygenase (FMO) system
Flavin-containing monooxygenases (FMOs) (EC 1.14.13.8) are a family of
microsomal NADPH-dependent oxidoreductase, responsible for oxygenation of
nucleophilic nitrogen, sulfur, phosphorus, other drugs, and endogenous molecules.
Different variants of mammalian FMOs play a significant role in the oxygenation of
nucleophilic xenobiotics. FMO utilizes NADPH as a cofactor and contains one FAD
as a prosthetic group. FMOs have a broad substrate specificity and their activity is
maximal at or above pH 8.4. FMO is a highly abundant enzyme in the liver
endoplasmic reticulum and participates in drug metabolism (activation and
detoxification) [29].
Before FMOs bind to a substrate, they activate molecular oxygen. First, flavin
adenine dinucleotide (FAD), the prosthetic group of FMO, is reduced by NADPH to
form FADH, then oxygen is added into the FAD, and hydro-peroxide FADH-4α-
OOH is produced. And then, one oxygen atom is transferred to the substrate [30, 31].
6.3 Metabolism of drugs through alcohol dehydrogenase and aldehyde
dehydrogenase
Alcohol dehydrogenase (ADH) and mitochondrial aldehyde dehydrogenase
(ALDH) are another family of oxidoreductase responsible for metabolizing ethanol.
These enzymes are highly expressed in the liver but at lower levels in many tissues
and play a great role in detoxification and easy removal of alcohols. Liver is the
main organ for ethanol metabolism. Oxidation of ethanol with these enzymes can
become a major energy source especially in the liver, and it can interfere metabo-
lism of other nutrients [32].
The first step in ethanol metabolism is its oxidation to acetaldehyde, and this
reaction is catalyzed by enzymes called alcohol dehydrogenases (ADHs). The sec-
ond reaction in ethanol metabolism is oxidation of acetaldehyde into acetate cata-
lyzed by aldehyde dehydrogenase (ALDH) enzymes. There are different ADH and
ALDH enzymes encoded by different genes occurring in several alleles and enzymes
that have different alcohol metabolizing capacity; thereby, they influence individ-
uals’ alcoholism risk. These are either through rapid oxidation of ethanol to acetal-
dehyde where there is more active ADH or slower oxidation of acetaldehyde into
acetate where there are less active ALDH enzymes. Excess accumulation of acetal-
dehyde is toxic, which results in different adverse reactions and produces nausea,
skin rash, rapid heartbeat, etc. Most commonly, single-nucleotide polymorphisms
(SNPs) are responsible for ADH and ALDH gene variants, and these may occur on
both coding and non-coding regions of the gene [33, 34].
6.4 Metabolism of drugs by monoamine oxidase (MAO)
Monoamine oxidase is a very important oxidoreductase enzyme mainly respon-
sible for degradation of amine neurotransmitters like norepinephrine, epinephrine,
serotonin, and dopamine. Oxidation of different endogenous and exogenous bio-
genic amines may produce other active or inactive metabolites. Monoamine oxidase
(MAO) is found in two isozyme forms: monoamine oxidase A (MAO-A)
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preferentially deaminates serotonin, norepinephrine, epinephrine, and dietary
vasopressors such as tyramine, and MAO-B preferentially deaminates dopamine
and phenethylamine. They are integral flavoproteins components of outer mito-
chondrial membranes in neurons and glia cell. The two isozymes of MAO differ
based on substrate specificity and sensitivity to different inhibitors [35].
Monoamine oxidase enzymes catalyze the primary catabolic pathway for 5-HT
oxidative deamination. Serotonin is converted into 5-hydroxy-indoleacetaldehyde,
and this product is further oxidized by a NAD-dependent aldehyde dehydrogenase
to form 5-hydroxyindoleacetic acid (5-HIAA). Immunohistochemical techniques
and in situ hybridization histochemistry techniques are used to study the neuroan-
atomical localization and biochemical nature of the two forms of MAO [36].
Different antidepressant drugs like phenelzine and tranylcypromine inhibit the
activity of monoamine oxidase. These are a result of MAO metabolizes biogenic
amines such as 5-HT, DA, and NE. In addition, different dopaminergic neurotoxins
such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) are metabolized by
MAO [37].
6.5 NADPH-cytochrome P450 reductase (CPR) in drug metabolism
Another essential class of oxidoreductase enzyme is NADPH-cytochrome P450
reductase (CPR). It is a membrane-bound protein localized in the ER membrane. PR
involves in the detoxification and activation of a number of xenobiotics. CPR uses
FAD and FMN as cofactors, and it transfers the hydride ion of NADPH to FAD, and
then FAD transfers electrons to FMN and other oxidases. Finally, it reduces the
P450 enzyme heme center to activate molecular oxygen. Thus, electrons transfer
from NADPH to the P450 heme center by CPR, which is central for P450-catalyzed
metabolism. Flow of electron can be expressed as follows:
NADPH! FAD! FMN! P450! O2 (7)
Human cytochrome P450 reductase is encoded by the POR gene. It is a 78-kDa
multi domain diflavin reductase that binds both FMN and FAD and is attached to
the cytoplasmic side of the endoplasmic reticulum via a transmembrane segment at
its N-terminus [5, 15, 38].
7. Industrial application of oxidoreductase enzymes
Several industries such as pharmaceutical, foods, biofuel production, natural gas
conversion, and others have used enzyme catalysis at commercial scale [39]. Classes
of oxidoreductase enzymes are becoming a target by a number of industries. The
family of oxidoreductase like heme-containing peroxidases and peroxygenases,
flavin-containing oxidases and dehydrogenases, and different copper-containing
oxidoreductases is involved in synthesis and degradation of interested products by
the above industries and they are biocatalysts of interest for establishing a bio-based
economy. Oxidoreductase enzymes have the highest potential in the production of
polymer building blocks, sustainable chemicals, and materials from plant biomass
within lignocellulose biorefineries [6, 7, 40].
7.1 Oxidoreductase enzymes in pharmaceutical industries
Enzymes are biological catalysts and have great specificity, efficiency, and
selectivity in the reaction they catalyze [39]. Oxidoreductase enzymes have
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different redox-active centers for doing their functions. These unique features of
oxidoreductase enzymes make it valuable targets of pharmaceutical and chemical
industries. Advancement in recombinant DNA technology, protein engineering,
and bioinformatics is a critical event in the application of enzymes in different
industries. A number of dug synthesis processes require the involvement of oxido-
reductase enzymes [6].
An oxidoreductase is involved in the synthesis of 3,4-dihydroxylphenyl alanine
(DOPA), and 3,4-dihydroxylphenyl alanine is a drug used for treatment of
Parkinson’s disease [41]. Similarly, a class of oxidoreductase called monoamine
oxidase (MAO) catalyzes enantiomeric desymmetrization of bicyclic proline inter-
mediate, which is an important precursor in the synthesis of boceprevir. Boceprevir
is a NS3 protease inhibitor that is used for the treatment of chronic hepatitis C
infections. Using MAO in this reaction reduces time and waste product generation
and is economically cost-competitive and profitable [42]. Its coenzyme specificity
makes oxidoreductase an effective biocatalyst in protein engineering [43]. In vitro
different oxidoreductase enzymes are involved in regeneration of coenzymes,
pyridine nucleotides, NAD(H) and NADP(H). Alcohol dehydrogenase and format
dehydrogenase are frequently used enzymes for recycling of coenzymes, and the
intermediate products are useful in the synthesis of pharmaceutical drugs such as
mevinic acid [44, 45].
7.2 Oxidoreductase enzymes in agricultural sector
Enzymes are biological catalysts and have a number of applications in agricul-
tural fields. Using enzymes has great efficacy and efficiency over chemical catalysts
with respect to their productivity, time, cost, quality, and quantity products. There
are different classes of oxidoreductase enzymes nowadays involved in fertilizer
production, dairy processing, and other food processing in agricultural sector, and
their cost-effectiveness and quality product were confirmed by a number of
researches [3].
Manipulation of gene cod for different oxidoreductase in plants can also change
the characters of plants in a way that it increases productivity and resists adverse
effects of herbicide and environmental changes. For example, modification of DNA
for glyphosate oxidoreductase (GOX) enzyme that catalyzes the oxidative cleavage
of the CdN bond on the carboxyl side of glyphosate, resulting in the formation of
aminomethylphosphonic acid (AMPA) and glyoxylate thereby augmented expres-
sion of GOX plants, results in glyphosate herbicide side effect tolerance [46, 47].
Some families of oxidoreductase like xanthine dehydrogenase in plants are used to
metabolize reactive oxygen species associated with plant-pathogen and protect
plants from stress-induced oxidative damage. Upregulation of xanthine dehydroge-
nase expression in plants is helpful to increase productivity [48, 49].
Classes of oxidoreductase are also involved in dairy processing. Glucose oxidase
produced by fungal species acts as preservatives in dairy products and other foods.
The intermediate and end product of glucose oxidase have antimicrobial effect [50].
Isozyme of xanthine oxidoreductase in bovine milk, which catalyzes reduction of
oxygen to generate reactive metabolite is used as an anti-microbial agent in the
neonatal gastrointestinal tract [51]. Similarly, peroxidases which are a family of
oxidoreductase found in higher plants catalyze the oxidation of many compounds
including phenolics, in the presence of hydrogen peroxide responsible in browning
or darkening of noodles and pasta and associated with a grain quality defect [52].
Protochlorophyllide oxidoreductase (POR), which exists in two isozymes POR A
and POR B, plays a vital role in plant chlorophyll synthesis, and manipulation on
these genes can induce plant development [53]. In general, there are a number of
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oxidoreductase enzymes found in plants, and their normal activity is crucial for
qualitative and quantitative productivity of crops, and these were confirmed by a
number of active researches. Different interventions are also going on at gene level
to control the expression of oxidoreductase enzymes in plant as needed [3].
8. Disease related with oxidoreductase enzyme disorder
Oxidoreductase enzymes are involved in a number of valuable biochemical
reactions in the living organism, and their qualitative and quantitative normality is
essential. For example, one important class of oxidoreductase is xanthine oxidore-
ductase (XOR) that catalyzes oxidative hydroxylation of hypoxanthine to xanthine
then to uric acid and over activity XOR leads to hyperuricemia and concomitant
production of reactive oxygen species. In turn, hyperuricemia is confirmed as an
independent risk factor for a number of clinical conditions such as gout, cardiovas-
cular disease, hypertension, and others. Different urate-lowering drugs or XOR
inhibitors are nowadays implemented to prevent and manage hyperuricemia
disorder [9].
Another important class of oxidoreductase enzyme is cytochrome P450 oxido-
reductase (POR) that is essential for multiple metabolic processes. Cytochrome
P450 enzymes are involved in metabolism of steroid hormones, drugs, and xenobi-
otics. Nowadays, more than 200 different mutations and polymorphisms in POR
gene have been identified and cause a complex set of disorders. Deficiency of
cytochrome P450 oxidoreductase affects normal production of hormone; specifi-
cally, it affects steroid hormones, which are needed for normal development and
reproduction. This is highly linked with the reproductive system, skeletal system,
and other functions. Signs and symptoms can be seen from birth to adult age with
different severities. Individuals with moderate cytochrome P450 oxidoreductase
deficiency may have ambiguous external genitalia and have a high chance of infer-
tility but a normal skeletal structure [5, 16, 18].
Aldehyde dehydrogenase 2 (ALDH2) deficiency known as Asian glow or alcohol
flushing syndrome is a common genetic health problem that interferes with alcohol
metabolism, and ALDH2 is a classical family of oxidoreductase enzymes. It was
confirmed that ALDH2 deficiency results in the accumulation acetaldehyde, which
is a toxic metabolite of alcohol metabolism and responsible for a number of health
challenges like esophageal, head, and neck cancer. A number of researches conclude
that acetaldehyde is a group 1 carcinogenic metabolite [33, 54]. Similarly, mono-
amine oxidase deficiency, which is a family oxidoreductase enzyme, affects the
normal metabolism of serotonin and catecholamines. It is a rare X-linked disorder
characterized by mild intellectual disability, and behavioral challenges appear at
earlier age. Monoamine oxidase-A deficiency that occurs almost exclusively in
males has episodes of skin flushing, excessive sweating, headaches, and diarrhea.
Monoamine oxidase-A deficiency can be diagnosed by finding an elevated urinary
concentration of the monoamine oxidase-A substrates in combination with reduced
amounts of the monoamine oxidase products [36, 55].
Mitochondria generate huge amounts of energy (ATP) to eukaryotic cells
through oxidation of fats and sugars; and fatty acid β-oxidation and oxidative
phosphorylation are two metabolic pathways that are central to this process. Qual-
itative and quantitative normality of oxidoreductase enzymes involved in oxidative
phosphorylation and fatty acid oxidations are essential to get sufficient energy
(ATP) form metabolism. Deficiency of a complex I (NADH-CoQ oxidoreductase) is
common, and a well-characterized mitochondrial problem causes reduced ATP
production [56]. Complex I (NADH-CoQ oxidoreductase) is responsible for
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recycling of NADH to NAD+, and in turn, this is essential to sustain Krebs cycle and
glycolysis. Mutations in both nuclear and mitochondrial DNA for Complex I gene
are responsible for mitochondrial disease. Individuals with mitochondrial diseases
suffer from an energy insufficiency characterized by myopathies, neuropathy,
delayed development, cardiomyopathy, lactic acidosis, and others. Furthermore,
since mitochondria are a hub of metabolism, mitochondrial dysfunctions are highly
associated with metabolic diseases like hypertension, obesity, diabetes, neurode-
generative diseases, and even aging. Deficiency of complex I leads to elevation of
NADH levels in the mitochondria that inhibit pyruvate dehydrogenase and α-
ketoglutarate dehydrogenase. This condition completely inhibits Krebs cycle, and it
is measured by CO2 evolution from [
14C] labeled precursors. Similarly, complex II
(succinate:ubiquinone oxidoreductase) deficiency affects both fatty acid oxidation
and electron transport chain, and it induces retinopathies and encephalopathies
[57, 58].
Deficiency of the pyruvate dehydrogenase complex (PDHC), another class of
oxidoreductase enzymes, causes similar clinical and biochemical alteration in
energy production with complex I (NADH-CoQ oxidoreductase) [59]. Both TCA
cycle and respiratory chain can be affected by succinate dehydrogenase deficiency.
Deficiency of oxidoreductase enzymes involved in Krebs cycle affects all carbohy-
drate, protein, fat, and nucleic acid metabolism as it is a common pathway for
metabolism of the above macromolecules [60].
Oxidoreductase enzymes are also involved in bile acid synthesis. Classes of
oxidoreductase enzymes called 3beta-hydroxy-Delta (5)-C (27)-steroid oxidore-
ductase catalyze an early step of bile acids synthesis from cholesterol and are
encoded by HSD3B7 gene on chromosome 16p11.2-12. Mutations of HSD3B7
gene affect bile acids synthesis, cause development of progressive liver disease
characterized by cholestatic jaundice, malabsorption of lipids, and lipid-soluble
vitamins from the gastrointestinal tract, and finally progress to cirrhosis and liver
failure [61].
One important biomolecule that acts as a precursor for other molecules and a
component of cell membrane is cholesterol. Mammalian cells can get cholesterol
from de novo biosynthesis or uptake of exogenously derived cholesterol associated
with plasma low-density lipoprotein (LDL). 3-Hydroxy-3-methylglutaryl-
coenzyme A (HMG-CoA) reductase, which is a class of oxidoreductase, catalyzes
the rate-limiting steps of de novo cholesterol biosynthetic pathway and target for
manipulation pharmacologically. Under or over activity of HMG-CoA reductase can
disturb cholesterol homeostasis and lead to either hypercholesterolemia or
hypocholesterolemia. And disturbed cholesterol level associated with number seri-
ous clinical problem like atherosclerosis [62, 63].
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